CClinicalTrials.gg
Active, not recruitingNCT06182995ADAPTUpdated Aug 5, 2026

Anticipating Decline and Providing Therapy

An interventional study of Usual Care post-Intensive Care Unit (ICU) and Anticipating Decline and Providing Therapy (ADAPT) in Cognitive Impairment, Dementia and Post ICU Syndrome, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This pilot feasibility study will be a randomized control trial of usual care following Intensive Care Unit (ICU) discharge compared to the Anticipating Decline and Providing Therapy (ADAPT) screening and support intervention. The trial aims to enroll 120 older adults (age 60 or older).

Read the detailed description

Anticipating Decline and Providing Therapy (ADAPT) is a program designed to support the implementation of a routine post-ICU cognitive impairment screening and support intervention. The program includes a routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge. Patients with a screening assessment that may be consistent with cognitive impairment or dementia will receive additional resources including a specialized care plan developed by the Sticht Center for Healthy Aging and Alzheimer's Prevention. The specialized care plan is adapted from a health system-based dementia care intervention and designed to support post-ICU cognitive concerns. It was adapted with input from geriatrics, intensive care, and outpatient primary care clinicians. Also conducted are semi-structured interviews with 22 older adult ICU survivors and 6 primary care physicians to elicit preferences and the intervention was further adapted based on these results.

02

Conditions studied

  • Cognitive Impairment
  • Dementia
  • Post ICU Syndrome
  • Critical Illness
  • Cognitive Impairment, Mild

Keywords

  • Post ICU
  • Post-ICU Screening
  • older adults
  • aging
03

In context

Cognitive Dysfunction

3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's enrollment of 109 is above the median of 65 across 2,808 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,320 studies on the registry; 199 are open to participants now.

Of its 323 completed or terminated interventional studies of FDA-regulated products, 243 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 60 and older at time of discharge from intensive care unit
  • Minimum 72 hour Intensive Care Unit stay in an ICU at Atrium Health Wake Forest Baptist
  • Delirium during ICU stay as determined by positive Confusion Assessment Method (CAM)-ICU score, review of clinical - documentation, or discussion with clinical team
  • Primary care provider in the Atrium Health Wake Forest system or intention to follow with Primary Care Physician in Atrium Health system
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Death during initial hospitalization and/or discharge to Hospice
  • Life-expectancy \< 6 months from pre-existing illness (defined as diagnosis of metastatic cancer, cirrhosis, advanced heart failure, prior palliative care referral)
  • Acute Traumatic Brain Injury
  • Continued residence in skilled nursing facility or rehab that prevents ability to complete study telephone call at time of first cognitive screen attempt
  • Prior history of dementia in electronic health record
  • Language or communication barrier that prohibits intervention participation
  • Participant cannot identify family or caregiver contact or family/caregiver unwilling to participate
  • Subject or legally authorized representative (LAR) decline consent
  • Unstable telephone service for contact after hospital discharge
  • Primary residence outside of North Carolina
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Active comparator
    Usual Care

    routine clinic visits

    Behavioral: Usual Care post-Intensive Care Unit (ICU)

  • Experimental
    Anticipating Decline and Providing Therapy (ADAPT) care

    The program includes a routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge

    Behavioral: Anticipating Decline and Providing Therapy (ADAPT)

Interventions

  • BehavioralUsual Care post-Intensive Care Unit (ICU)

    routine clinic visits

    Also known as: routine clinic visits

  • BehavioralAnticipating Decline and Providing Therapy (ADAPT)

    routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge

    Also known as: Post-ICU cognitive screening

06

What researchers measure

Primary outcomes

  1. Number of participants in Cognitive Screening Intervention Arm

    Number of participants in intervention arm who complete cognitive screening at 6 weeks

    Time frame: Week 6

Secondary outcomes

  1. Change in Percentage of participants having mild cognitive impairment (MCI), probable dementia and the combination of either MCI or probable dementia

    percentage of participants adjudicated as having mild cognitive impairment (MCI), probable dementia and the combination of either MCI or probable dementia

    Time frame: Week 28

  2. Change in number of Participants between those enrolled and those who were eligible but declined

    compare pre-specified baseline characteristics (i.e., age, sex, race, ICU length of stay) between those enrolled and those who were eligible but declined

    Time frame: Week 52

  3. Number of eligible participants who complete specialized care plan development visit

    Number of eligible participants who complete specialized care plan development visit

    Time frame: up to week 28

  4. Change in Modified Caregiver Strain Index (MCSI) Scores

    the modified caregiver strain index will be assessed via telephone call to identified caregiver or care partner in both groups - a 13-question tool that measures strain related to care provision - Scoring is 2 points for each 'yes', and 1 point for each 'sometimes' response. The higher the score, the higher the level of caregiver strain - range of 13-26

    Time frame: Week 28

  5. Change in the number of hospitalizations and Emergency Department visits

    healthcare utilization will be the number of hospitalizations and Emergency Department (ED) visits

    Time frame: Month 12

  6. Change in the Number of neuropsychiatric prescriptions medications

    number of neuropsychiatric prescriptions medications will be measured using the electronic health record

    Time frame: Month 12

  7. Change in number of new diagnoses of dementia or mild cognitive impairment

    new diagnosis of dementia or mild cognitive impairment will be measured using the electronic health record

    Time frame: Month 12

  8. Acceptability of Intervention Measure (AIM) Scores

    The Acceptability of Intervention Measure (AIM) - Response Scale - 4 item scales. Each item will be measured on a 5 point Likert scale: 1 = Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Completely agree - The score is calculated mean. Higher scores reflect higher measure of acceptability

    Time frame: Week 28

  9. Acceptability of Intervention Appropriateness Measure (IAM) Scores

    Intervention Appropriateness Measure (IAM) - Response Scale - 4 item scales. Each item will be measured on a 5 point Likert scale: 1 = Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Completely agree - The score is calculated mean. Higher scores reflect higher measure of appropriateness

    Time frame: Week 28

  10. Acceptability of Feasibility of Intervention measure (FIM) Scores

    The Acceptability of Feasibility of Intervention Measure (FIM) - Response Scale - 4 item scales. Each item will be measured on a 5 point Likert scale: 1 = Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Completely agree - The score is calculated mean. Higher scores reflect higher measure of feasibility

    Time frame: Week 28

Other outcomes

  1. Qualitative Perception

    semi-structured interviews with participants for feedback about the intervention - this will not be a numerical score

    Time frame: Week 28

07

Study locations

1 site
  • Atrium Health Wake Forest Baptist
    Winston-Salem, North Carolina 27157, United States
08

References and documents

Study documents

  • Informed consent form · Nov 3, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06182995
Lead sponsor
Wake Forest University Health Sciences
Collaborators
National Institute on Aging (NIA)
Responsible party
Sponsor
First posted
Dec 27, 2023
Start date
Mar 8, 2024
Primary completion
Mar 1, 2026
Completion
Feb 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Jessica Palakshappa, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion